Jason Gerberry
Stock Analyst at B of A Securities
(4.23)
# 388
Out of 5,182 analysts
169
Total ratings
61.6%
Success rate
11.06%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $38 → $42 | $31.26 | +34.36% | 16 | Apr 9, 2026 | |
| PFE Pfizer | Maintains: Neutral | $27 → $26 | $26.79 | -2.95% | 6 | Apr 9, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $100 → $111 | $72.23 | +53.68% | 8 | Apr 9, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $34 → $36 | $33.73 | +6.73% | 11 | Apr 9, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,293 → $1,294 | $868.27 | +49.03% | 16 | Apr 2, 2026 | |
| LENZ LENZ Therapeutics | Maintains: Buy | $35 → $29 | $9.76 | +197.13% | 1 | Mar 25, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $201.22 | +36.67% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $31.05 | -9.82% | 3 | Feb 25, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $73.60 | +10.05% | 4 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $27.11 | +6.97% | 4 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $32 | $21.65 | +47.81% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $28.62 | +4.82% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $9.59 | +410.95% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $187.40 | -6.08% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $1.86 | -46.24% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $37.34 | -38.40% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $44.65 | +3.02% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $59.72 | +129.40% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $14.81 | -32.48% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $29.27 | +2.49% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $115.07 | -13.10% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $14.95 | +60.54% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.55 | +8.58% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $54.26 | +3.21% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.25 | +300.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $13.16 | +89.97% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.56 | +220.51% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.58 | +383.87% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.84 | +986.96% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $6.83 | +1,365.20% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $197.38 | -51.87% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $57.78 | +3.84% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $110.23 | -18.35% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
Apr 9, 2026
Maintains: Buy
Price Target: $38 → $42
Current: $31.26
Upside: +34.36%
Pfizer
Apr 9, 2026
Maintains: Neutral
Price Target: $27 → $26
Current: $26.79
Upside: -2.95%
Ionis Pharmaceuticals
Apr 9, 2026
Maintains: Buy
Price Target: $100 → $111
Current: $72.23
Upside: +53.68%
Alkermes
Apr 9, 2026
Maintains: Neutral
Price Target: $34 → $36
Current: $33.73
Upside: +6.73%
Eli Lilly and Company
Apr 2, 2026
Maintains: Buy
Price Target: $1,293 → $1,294
Current: $868.27
Upside: +49.03%
LENZ Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $35 → $29
Current: $9.76
Upside: +197.13%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $201.22
Upside: +36.67%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $31.05
Upside: -9.82%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $73.60
Upside: +10.05%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $27.11
Upside: +6.97%
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $21.65
Upside: +47.81%
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $28.62
Upside: +4.82%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $9.59
Upside: +410.95%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $187.40
Upside: -6.08%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $1.86
Upside: -46.24%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $37.34
Upside: -38.40%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $44.65
Upside: +3.02%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $59.72
Upside: +129.40%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $14.81
Upside: -32.48%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $29.27
Upside: +2.49%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $115.07
Upside: -13.10%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $14.95
Upside: +60.54%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.55
Upside: +8.58%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $54.26
Upside: +3.21%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.25
Upside: +300.00%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $13.16
Upside: +89.97%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.56
Upside: +220.51%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.58
Upside: +383.87%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.84
Upside: +986.96%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $6.83
Upside: +1,365.20%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $197.38
Upside: -51.87%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $57.78
Upside: +3.84%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $110.23
Upside: -18.35%